Wockhardt

Wockhardt

1,518.00
-9.30
(-0.61%)
ann
There are new updates from the company22 hours ago
Viewcross
right
Market Cap
24,665.31 Cr
EPS
-3.02
PE Ratio
-
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
1,868.80
52 Week Low
915.00
PB Ratio
5.70
Debt to Equity
0.57
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
neutral
Wockhardt Targets Healthy Profits After US Business Exit Despite Rising LossesAug 12, 2025
Wockhardt reported a consolidated net loss of Rs 108 crore in Q1FY26, significantly higher than Rs 16 crore loss in Q1FY25. Founder Chairman Habil Khorakiwala attributed the increased loss to a one-time goodwill write-off from exiting the loss-making US generics business and upfront costs for new drug Miqnaf. The company expects a healthy bottom line in coming quarters following the US exit. Wockhardt's flagship antibiotic Zaynich, manufactured in Europe, will remain unaffected by potential US-India trade tariffs. The company plans to file a New Drug Application with USFDA for Zaynich in September 2025, expecting approval by mid-2026, while anticipating commercial launch in India by early 2026. Clinical trials for another antibiotic Foviscu are expected to conclude by October 2025. Khorakiwala believes US tariffs will have limited impact on Indian pharma sector due to manufacturing complexities and potential drug shortages. Wockhardt shares traded 0.69% lower at Rs 1,462.1 on NSE.
neutral
Wockhardt Limited submitted its monitoring agency report for the quarter ended June 30, 2025, confirming no deviation from stated objectives in utilizing proceeds from its Qualified Institutions Placement of approximately ₹1,000 crore. The report was issued by CRISIL Ratings Limited and shows total utilization of ₹583.08 crore out of net proceeds of ₹977.79 crore, leaving ₹394.71 crore unutilized. The funds were allocated across three objectives: ₹500 crore for debt repayment (₹416.31 crore utilized), ₹250 crore for capital expenditure and R&D (₹32.77 crore utilized), and ₹227.79 crore for general corporate purposes (₹134 crore utilized). Unutilized proceeds of ₹394.71 crore are invested in various mutual funds earning ₹13.20 crore in returns. The QIP was conducted from November 6-11, 2024, with net proceeds revised upward by ₹3.82 crore due to lower actual issue expenses than estimated.
positive
Wockhardt has completed two pre-New Drug Application (NDA) meetings with the US Food and Drug Administration. The pharmaceutical company aims to file its New Drug Application by September 2025.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,616.60
#1 3,87,876.49
33.67
#1 54,729.00
9.71
#1 10,980
-19.84
49.00
6,026.50
1,59,984.64
69.22
9,712.00
18.67
2,191
26.74
39.47
1,574.60
1,27,181.67
23.38
28,409.50
7.12
5,291
9.88
52.08
3,566.20
1,20,696.41
60.00
11,539.40
6.99
1,911
19.91
48.74
1,316.70
1,09,887.98
#1 19.15
33,741.20
16.73
5,725
1.26
60.35
2,579.60
1,06,467.51
56.70
12,744.20
#1 20.90
2,007
-18.14
58.41
1,044.75
1,05,126.30
22.52
23,511.00
18.55
4,615
2.60
68.18
2,043.40
93,321.15
24.55
22,909.50
13.74
3,306
#1 51.64
59.44
30,980.00
65,830.34
45.32
6,684.70
9.64
1,414
11.55
39.39
5,448.00
65,139.01
28.38
13,458.30
3.70
2,216
21.39
63.73
Forecast
Actual
Growth Rate
Revenue Growth
6.70 %
Net Income Growth
-87.92 %
Cash Flow Change
-110.05 %
ROE
-90.54 %
ROCE
-264.98 %
EBITDA Margin (Avg.)
249.88 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
1,052
1,160
1,206
1,116
1,028
1,108
1,083
1,018
920
928
1,077
1,042
1,010
1,015
1,132
1,048
880
760
705
807
720
2,077
730
865
640
861
866
856
669
652
736
701
710
658
777
709
754
769
818
729
758
758
Expenses
943
973
1,031
1,001
945
1,016
964
995
1,028
1,309
1,001
959
1,024
1,003
1,058
1,064
827
726
670
656
674
1,298
697
706
698
739
765
742
871
611
831
657
771
642
681
664
803
648
699
593
679
763
EBITDA
109
187
175
116
83
92
119
23
-108
-381
76
84
-15
12
74
-16
53
34
35
151
47
779
33
159
-58
122
101
114
-202
41
-95
44
-61
16
96
45
-49
121
119
136
79
-5
Operating Profit %
13 %
15 %
16 %
7 %
6 %
7 %
9 %
0 %
-19 %
-47 %
2 %
5 %
-1 %
0 %
6 %
-2 %
4 %
-0 %
2 %
12 %
2 %
-117 %
2 %
8 %
-10 %
14 %
11 %
13 %
-33 %
-3 %
-22 %
6 %
-14 %
0 %
10 %
5 %
-15 %
12 %
14 %
18 %
9 %
-3 %
Depreciation
34
35
35
36
37
36
37
38
37
37
36
38
38
39
40
41
45
55
53
56
61
56
57
68
65
64
61
62
59
64
65
66
56
55
55
55
58
54
55
55
53
56
Interest
14
24
30
32
43
49
56
61
59
61
68
62
65
73
65
64
64
71
65
79
61
74
61
60
55
64
69
80
86
73
70
83
76
79
76
77
73
73
73
60
48
48
Profit Before Tax
60
128
110
48
4
7
26
-76
-204
-480
-28
-16
-118
-100
-32
-121
-55
-92
-82
16
-75
649
-85
31
-178
-6
-29
-28
-347
-96
-230
-105
-193
-118
-35
-87
-180
-6
-9
21
-22
-109
Tax
27
30
12
-22
17
-9
1
-16
3
-17
-19
27
35
-5
-1
-44
-41
-55
12
-3
-144
-111
-88
-1
-71
1
-66
-30
-36
-21
-23
-3
44
18
38
-1
-3
10
7
1
23
-1
Net Profit
33
98
98
69
-13
17
25
-60
-207
-463
-9
-43
-153
-95
-31
-77
-14
-37
-94
19
69
760
3
32
-107
-7
37
2
-311
-75
-207
-102
-237
-136
-73
-86
-177
-16
-16
20
-45
-108
EPS in ₹
3.10
8.36
8.37
6.52
-0.49
1.44
2.25
-4.88
-15.81
-37.06
-0.80
-3.69
-13.97
-7.79
-2.06
-6.42
-2.62
-4.06
-7.42
0.87
4.36
68.64
0.32
1.38
-8.38
-1.15
2.79
-0.61
-21.20
-4.64
-13.15
-6.62
-14.37
-9.28
-5.37
-5.75
-11.64
-0.95
-1.47
0.91
-1.57
-5.53

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
6,939
8,121
9,022
8,162
7,844
8,179
7,774
8,243
7,683
7,649
8,135
Fixed Assets
2,123
2,809
2,773
2,888
3,058
3,502
3,343
3,462
3,042
2,881
2,736
Current Assets
3,522
3,952
4,535
3,380
2,815
2,430
2,425
2,589
2,208
2,073
2,465
Capital Work in Progress
1,007
1,036
1,244
1,433
1,446
1,585
1,379
1,342
1,539
1,722
2,033
Investments
339
0
563
214
0
0
0
0
0
0
422
Other Assets
3,470
4,276
4,443
3,628
3,341
3,092
3,052
3,439
3,102
3,046
2,944
Total Liabilities
6,939
8,121
9,022
8,162
7,844
8,179
7,774
8,243
7,683
7,649
8,135
Current Liabilities
1,773
1,842
1,979
2,692
2,864
3,497
3,121
3,207
3,435
2,791
2,042
Non Current Liabilities
1,307
2,039
3,324
2,272
1,976
1,624
894
834
586
1,196
1,436
Total Equity
3,859
4,241
3,719
3,198
3,005
3,058
3,759
4,202
3,662
3,662
4,657
Reserve & Surplus
3,362
3,720
3,281
2,797
2,620
2,616
3,321
3,777
3,282
3,282
4,272
Share Capital
354
55
55
55
55
55
55
72
72
77
81

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
57
46
301
-66
-500
-178
13
138
-280
415
-393
Investing Activities
-222
-106
-684
635
93
-147
1,471
-204
-118
-138
-780
Operating Activities
355
-42
-270
68
183
649
-287
413
153
219
-22
Financing Activities
-76
193
1,255
-770
-777
-680
-1,171
-71
-315
334
409

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Nov 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
72.12 %
69.68 %
68.04 %
67.13 %
67.13 %
65.75 %
63.83 %
60.36 %
59.31 %
58.40 %
55.14 %
54.93 %
51.60 %
51.99 %
51.99 %
49.09 %
49.09 %
49.09 %
49.09 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.02 %
0.00 %
5.49 %
5.93 %
6.70 %
6.62 %
6.54 %
6.81 %
7.29 %
DIIs
0.02 %
0.02 %
0.02 %
0.03 %
0.03 %
0.03 %
0.03 %
0.23 %
0.22 %
0.19 %
0.22 %
0.10 %
4.83 %
4.45 %
5.09 %
9.88 %
9.82 %
10.59 %
11.01 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.02 %
0.02 %
0.02 %
0.02 %
0.02 %
Public / Retail
21.41 %
23.02 %
25.24 %
25.99 %
24.56 %
25.97 %
27.42 %
30.26 %
31.45 %
32.19 %
32.89 %
32.94 %
29.94 %
30.18 %
29.02 %
27.45 %
27.49 %
26.69 %
26.05 %
Others
6.46 %
7.27 %
6.69 %
6.85 %
8.28 %
8.26 %
8.72 %
9.15 %
9.02 %
9.21 %
8.72 %
12.03 %
8.13 %
7.43 %
7.19 %
6.95 %
7.04 %
6.80 %
6.55 %
No of Share Holders
0
0
1,25,128
1,44,845
1,61,625
1,65,270
1,66,122
1,80,170
1,80,630
1,78,915
1,72,989
1,61,813
1,46,376
1,40,391
1,38,142
1,43,876
1,42,710
1,41,799
1,46,918

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield (%) 0.00 1.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
09 Mar 2022 RIGHTS Rights
3:10
08 Mar 2022 311.72 308.20
28 Jun 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
28 Jun 2024 514.90 653.75
13 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2024 1,206.50 1,180.80
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Feb 2025 1,558.55 1,651.10
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 1,320.20 1,337.10
08 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 Aug 2025 1,667.50 1,519.15
08 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2025 1,828.00 1,519.15

Announcements

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - ESG Ratings22 hours ago
Announcement under Regulation 30 (LODR)-Credit RatingAug 26, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 21, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 08, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 08, 2025
Outcome Of The Board MeetingAug 08, 2025
Board Meeting Outcome for Outcome Of The Board MeetingAug 08, 2025
Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited ("The Company").Aug 01, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 31, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 28, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 16, 2025
Intimation Of Record Date For The Purpose Of 25Th Annual General Meeting (AGM) Of The Company.Jul 16, 2025
Notice Of 26Th Annual General Meeting(AGM) Of The Company For The Financial Year 2024-25Jul 16, 2025
Reg. 34 (1) Annual Report.Jul 16, 2025
Reg. 34 (1) Annual Report.Jul 16, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 11, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJun 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJun 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 29, 2025
Board Meeting Outcome for Outcome Of The Board MeetingMay 29, 2025
Board Meeting Outcome for Outcome Of The Board MeetingMay 29, 2025
Outcome Of The Board MeetingMay 29, 2025
Board Meeting Intimation for Pursuant To Regulation 29(1) (A) And (D) Of SEBI LODR Regulations We Wish To Inform You That A Meeting Of The Board Of Directors Of The Company Will Be Held On Thursday 29Th May 2025May 23, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportMay 14, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 11, 2025
Intimation For Incorporation Of A Step-Down Subsidiary Company Apr 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Closure of Trading WindowMar 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 14, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 14, 2025
Integrated Filing (Financial)Feb 07, 2025
Statement On Deviation Or Variation Of Funds Raised Through Qualified Institutions Placements For The Quarter Ended 31St December 2024Feb 07, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2025
Board Meeting Outcome for Outcome Of The Board MeetingFeb 07, 2025
Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited Feb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 31, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 02, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 16, 2024

Technical Indicators

RSI(14)
Neutral
50.97
ATR(14)
Less Volatile
54.66
STOCH(9,6)
Neutral
66.85
STOCH RSI(14)
Overbought
84.84
MACD(12,26)
Bullish
16.42
ADX(14)
Weak Trend
18.33
UO(9)
Bearish
41.28
ROC(12)
Uptrend And Accelerating
3.25
WillR(14)
Neutral
-36.57

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan Small Cap Fund Direct-Growth
0.56%
76850
-0.03%
-0.07%
Bank of India Small Cap Fund Direct-Growth
1.63%
50000
0.21%
0.06%
Samco Active Momentum Fund Direct - Growth
1.54%
-47235
-1.09%
-4.54%
ITI Small Cap Fund Direct-Growth
1.71%
28031
-0.07%
-0.06%
Bandhan Multi Cap Fund Direct-Growth
0.35%
-24057
-0.21%
-0.22%
ITI Flexi Cap Fund Direct - Growth
1.36%
-15389
-0.43%
-0.61%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.12%
-8961
-0.10%
-0.11%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.62%
3906
0.62%
0.62%
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
0.63%
3002
-0.08%
-0.07%
Bandhan Aggressive Hybrid Fund Direct-Growth
0.44%
2494
-0.07%
-0.07%
ITI Mid Cap Fund Direct - Growth
1.40%
2381
-0.17%
-0.19%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.63%
1331
-0.08%
-0.07%
SBI Nifty Smallcap 250 Index Fund Direct - Growth
0.63%
1188
-0.07%
-0.07%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.63%
914
-0.08%
-0.07%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.63%
720
-0.08%
-0.07%
ITI Value Fund Direct - Growth
1.72%
637
-0.20%
-0.22%
ITI Pharma and Healthcare Fund Direct - Growth
2.49%
595
-0.27%
-0.42%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.62%
481
-0.08%
-0.08%
Motilal Oswal Nifty 500 Index Fund Direct - Growth
0.06%
203
-0.01%
-0.01%
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
0.17%
-171
-0.03%
-0.03%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.63%
147
-0.08%
-0.07%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.63%
128
-0.07%
-0.07%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.63%
87
-0.08%
-0.07%
Axis Nifty 500 Index Fund Direct-Growth
0.06%
67
-0.01%
-0.01%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.15%
-52
-0.03%
-0.02%